TESTODERM TTS Drug Patent Profile
✉ Email this page to a colleague
When do Testoderm Tts patents expire, and when can generic versions of Testoderm Tts launch?
Testoderm Tts is a drug marketed by Alza and is included in one NDA.
The generic ingredient in TESTODERM TTS is testosterone. There are sixty-nine drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the testosterone profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Testoderm Tts
A generic version of TESTODERM TTS was approved as testosterone by ACTAVIS LABS UT INC on January 27th, 2006.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for TESTODERM TTS?
- What are the global sales for TESTODERM TTS?
- What is Average Wholesale Price for TESTODERM TTS?
Summary for TESTODERM TTS
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 73 |
Patent Applications: | 4,288 |
DailyMed Link: | TESTODERM TTS at DailyMed |
US Patents and Regulatory Information for TESTODERM TTS
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Alza | TESTODERM TTS | testosterone | FILM, EXTENDED RELEASE;TRANSDERMAL | 020791-001 | Dec 18, 1997 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for TESTODERM TTS
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Alza | TESTODERM TTS | testosterone | FILM, EXTENDED RELEASE;TRANSDERMAL | 020791-001 | Dec 18, 1997 | ⤷ Sign Up | ⤷ Sign Up |
Alza | TESTODERM TTS | testosterone | FILM, EXTENDED RELEASE;TRANSDERMAL | 020791-001 | Dec 18, 1997 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
EU/EMA Drug Approvals for TESTODERM TTS
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Warner Chilcott UK Ltd. | Intrinsa | testosterone | EMEA/H/C/000634 Intrinsa is indicated for the treatment of hypoactive sexual desire disorder (HSDD) in bilaterally oophorectomised and hysterectomised (surgically induced menopause) women receiving concomitant estrogen therapy. |
Withdrawn | no | no | no | 2006-07-28 | |
Warner ChilcottĀ Deutschland GmbH | Livensa | testosterone | EMEA/H/C/000630 Livensa is indicated for the treatment of hypoactive sexual desire disorder (HSDD) in bilaterally oophorectomised and hysterectomised (surgically induced menopause) women receiving concomitant estrogen therapy. |
Withdrawn | no | no | no | 2006-07-28 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for TESTODERM TTS
See the table below for patents covering TESTODERM TTS around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Sweden | 452407 | ENHETSDOSFORM | ⤷ Sign Up |
Mexico | 161285 | MEJORAS A VENDAJE O PARCHE PARA COADMINISTRAR UNA DROGA Y UN MEJORADOR DE ABSORCION PERCUTANEA A UN AREA PREDETERMINADA DE PIEL NO ROTA,DURANTE UN TIEMPO PREDETERMINADO | ⤷ Sign Up |
Australia | 547007 | ⤷ Sign Up | |
Australia | 565178 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |